This study is currently not recruiting participants.

A Phase 1b/2 Multicenter Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated Unresectable Stage IIIb-IV Melanoma

Investigating a Combination Treatment for Advanced Melanoma

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to find out more about talimogene laherparepvec, in people with advanced melanoma when given in combination with another drug called ipilimumab.

Detailed description of study

The purpose of this study is to evaluate the safety of talimogene laherparepvec in combination with ipilimumab and to evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Melanoma
  • Age: 18 years - 100 years
  • Gender: All

This study investigates a treatment for advanced melanoma, a type of skin cancer. The study looks at using an investigational medication in combination with another drug to see how safe and effective it is compared to using the other drug alone.

Participants in this study will receive either the investigational medication with the other drug or the other drug by itself. The study will monitor the safety and effects of these treatments to understand their benefits and risks.

  • Who can participate: Key eligibility criteria include adults diagnosed with advanced melanoma. Participants should be within a specified age range and meet certain health conditions related to advanced melanoma.
  • Study details: Participants will receive either the investigational medication with another drug or the other drug alone. The study will monitor their reactions to these treatments.
Updated on 19 Feb 2024. Study ID: 1305011360 (20110264)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team